NYSE:EBS - Emergent Biosolutions Stock Price, Forecast & News

Emergent Biosolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Emergent Biosolutions announced that its Board of Directors has approved a share repurchase plan on Friday, March 23rd 2018, which authorizes the company to buyback $50,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock buyback plans are often a sign that the company's board believes its shares are undervalued.

Emergent Biosolutions Inc (NYSE:EBS) issued its quarterly earnings results on Thursday, February, 20th. The biopharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.67 by $0.10. The biopharmaceutical company had revenue of $360.40 million for the quarter, compared to the consensus estimate of $357.18 million. Emergent Biosolutions had a return on equity of 14.19% and a net margin of 4.94%. Emergent Biosolutions's revenue for the quarter was up 33.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. View Emergent Biosolutions' Earnings History.

Emergent Biosolutions is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Emergent Biosolutions.

Emergent Biosolutions issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 20th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.175-1.275 billion, compared to the consensus revenue estimate of $1.23 billion.

6 Wall Street analysts have issued twelve-month target prices for Emergent Biosolutions' shares. Their forecasts range from $64.00 to $75.00. On average, they expect Emergent Biosolutions' stock price to reach $69.00 in the next twelve months. This suggests a possible upside of 10.8% from the stock's current price. View Analyst Price Targets for Emergent Biosolutions.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Emergent Biosolutions in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Emergent Biosolutions.

Media coverage about EBS stock has trended somewhat positive recently, according to InfoTrie. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Emergent Biosolutions earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Emergent Biosolutions.

Emergent Biosolutions saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,610,000 shares, an increase of 6.5% from the January 15th total of 2,450,000 shares. Based on an average daily volume of 307,300 shares, the days-to-cover ratio is presently 8.5 days. Currently, 6.1% of the company's stock are sold short. View Emergent Biosolutions' Current Options Chain.

Some companies that are related to Emergent Biosolutions include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent Biosolutions investors own include Mercadolibre (MELI), Broadcom (AVGO), Global Payments (GPN), Netflix (NFLX), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), NXP Semiconductors (NXPI), CalAmp (CAMP) and Gentherm (THRM).

Emergent Biosolutions' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (4.00%), Earnest Partners LLC (3.94%), Goldman Sachs Group Inc. (2.18%), Rice Hall James & Associates LLC (2.13%), Renaissance Technologies LLC (1.48%) and Jennison Associates LLC (1.24%). Company insiders that own Emergent Biosolutions stock include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Ronald Richard, Sue Bailey and Zsolt Harsanyi. View Institutional Ownership Trends for Emergent Biosolutions.

EBS stock was sold by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Renaissance Technologies LLC, Tygh Capital Management Inc., Marshall Wace LLP, Rice Hall James & Associates LLC, Mutual of America Capital Management LLC, UBS Group AG and Bank of America Corp DE. Company insiders that have sold Emergent Biosolutions company stock in the last year include Adam Havey, Daniel Abdun-Nabi, Fuad El-Hibri, Kathryn C Zoon, Sue Bailey and Zsolt Harsanyi. View Insider Buying and Selling for Emergent Biosolutions.

EBS stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Earnest Partners LLC, Eaton Vance Management, State Street Corp, Loomis Sayles & Co. L P, Goldman Sachs Group Inc., FMR LLC and Prudential Financial Inc.. View Insider Buying and Selling for Emergent Biosolutions.

Shares of EBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EBS stock can currently be purchased for approximately $62.28.

Emergent Biosolutions has a market capitalization of $3.21 billion and generates $1.11 billion in revenue each year. The biopharmaceutical company earns $54.50 million in net income (profit) each year or $2.91 on an earnings per share basis. Emergent Biosolutions employs 1,705 workers across the globe.View Additional Information About Emergent Biosolutions.

The official website for Emergent Biosolutions is http://www.emergentbiosolutions.com/.

Emergent Biosolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The biopharmaceutical company can be reached via phone at 240-631-3200 or via email at [email protected]